Pharmacological cardioversion of supraventricular tachycardia in pregnancy during continuous electrophysiological foetal monitoring: a case report.
- Resource Type
- Report
- Authors
- Francinetti A; Departement of Gynaecology and Obstetrics UZA, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.; Vullings R; Signal Processing Systems group, Eindhoven University of Technology, 5612 AZ Eindhoven, Netherlands.; Dewals W; Departement of Pediatric Cardiology UZA, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.; Jochems L; Departement of Gynaecology and Obstetrics UZA, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.
- Source
- Publisher: Oxford University Press Country of Publication: England NLM ID: 101730741 Publication Model: eCollection Cited Medium: Internet ISSN: 2514-2119 (Electronic) Linking ISSN: 25142119 NLM ISO Abbreviation: Eur Heart J Case Rep Subsets: PubMed not MEDLINE
- Subject
- Language
- English
Background: Maternal tachycardia is the most frequently occurring cardiac complication during pregnancy. Often administration of drugs is required as a treatment. The drug of choice is intravenously administered adenosine because it is considered safe, though there are limited studies regarding safety for the foetus with the use of adenosine.
Case Summary: We report a conversion of maternal atrio-ventricular (AV) nodal reentry tachycardia during pregnancy with the use of intravenous adenosine whilst continuous electrophysiological foetal monitoring. Four seconds after the maternal conversion, the foetal tracing suggests the presence of a ventricular extrasystole or a transient AV block.
Discussion: This case report illustrates that the administration of adenosine intravenously during pregnancy could have an effect on the foetal conduction system. Therefore, further investigation to assess the electrophysiological effect of adenosine on the foetal electrocardiogram seems required.
(© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.)